REGENXBIO Balance Sheet Health
Financial Health criteria checks 4/6
REGENXBIO has a total shareholder equity of $311.7M and total debt of $94.1M, which brings its debt-to-equity ratio to 30.2%. Its total assets and total liabilities are $574.0M and $262.2M respectively.
Key information
30.2%
Debt to equity ratio
US$94.05m
Debt
| Interest coverage ratio | n/a |
| Cash | US$275.26m |
| Equity | US$311.74m |
| Total liabilities | US$262.23m |
| Total assets | US$573.97m |
Recent financial health updates
We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09
Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Recent updates
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration
Oct 03Regenxbio: A Transformative Year
Sep 15Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development
Aug 29Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%
Aug 03Regenxbio: Patience And Regular Homework Are Keys
Jul 12REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Slashed This Year's Estimates
Jun 27The Strong Earnings Posted By REGENXBIO (NASDAQ:RGNX) Are A Good Indication Of The Strength Of The Business
May 12Regenxbio: Is The Ultimate Catalyst Coming?
Apr 20Financial Position Analysis
Short Term Liabilities: RGNX's short term assets ($335.0M) exceed its short term liabilities ($130.3M).
Long Term Liabilities: RGNX's short term assets ($335.0M) exceed its long term liabilities ($132.0M).
Debt to Equity History and Analysis
Debt Level: RGNX has more cash than its total debt.
Reducing Debt: RGNX's debt to equity ratio has increased from 0% to 30.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RGNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RGNX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.